January 16, 2018 11:01 AM EST

FDA commissioner Scott Gottlieb just broke a public promise on publishing CRLs — and yes, it matters

In his testimony to the US Senate during his confirmation hearings to lead the FDA, Scott Gottlieb clearly enunciated his position on publishing the …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

FDA commissioner Scott Gottlieb just broke a public promise on publishing CRLs — and yes, it matters

This article is available only to Premium subscribers

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

FDA com­mis­sion­er Scott Got­tlieb just broke a pub­lic promise on pub­lish­ing CRLs — and yes, it mat­ters

This article is available only to Premium subscribers

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

FDA commissioner Scott Gottlieb just broke a public promise on publishing CRLs — and yes, it matters

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?